Ascendis Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	495.93	-228.03	-378.08	-481.45	-583.19	-383.58
Depreciation & Amortization	17.49	17.7	17.71	18.91	17.96	15.39
Stock-Based Compensation	120.97	116.17	95.51	66.66	64.18	66.83
Other Adjustments	-521.97	83.78	71.33	32.77	17.83	-68.72
Change in Receivables	-118.82	15.59	-118.61	-32.77	-11.53	-6.66
Changes in Inventories	-21.27	-5.92	-86.68	-78.26	-55.27	-75.41
Changes in Accounts Payable	9.34	-10.37	26.97	3.55	45.94	39.19
Changes in Income Taxes Payable	-5.46	-6.68	-5.51	-4.47	-0	0.15
Changes in Unearned Revenue	5.92	0.13	-1.2	-7.08	8.65	5.2
Changes in Other Operating Activities	78.48	71.53	72.36	14.77	-0.26	-10.05
Operating Cash Flow	60.49	53.9	-306.2	-467.36	-495.7	-417.65
Capital Expenditures	-	-	-	-	-	-23.7
Sale of Property, Plant & Equipment	-	-	0.95	0.05	-	-
Purchases of Intangible Assets	-15.49	-8.49	-1.43	-2.44	-14.49	-0.53
Purchases of Investments	-	-	-	-	-213.84	-236.23
Proceeds from Sale of Investments	-	-	7.35	288.87	280.53	149.88
Other Investing Activities	0.96	-	-	-	9.54	-
Investing Cash Flow	-14.54	-8.49	6.88	286.47	61.73	-110.58
Long-Term Debt Issued	-	-	134.16	136.26	503.28	-
Long-Term Debt Repaid	-27.47	-21.96	-11.37	-10.44	-6.36	-
Net Long-Term Debt Issued (Repaid)	-27.47	-21.96	122.79	125.82	496.93	-
Issuance of Common Stock	104.87	87.08	340.43	10.29	5.15	379.42
Repurchase of Common Stock	-51.86	-17.4	-	-	-105.31	-21.61
Net Common Stock Issued (Repurchased)	53.01	69.68	340.43	10.29	-100.15	357.82
Other Financing Activities	-8.02	-11.4	-19.29	-1.81	-	-6.43
Financing Cash Flow	17.52	36.33	443.93	134.29	396.77	351.39
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-8.58	-25.24	22.77	-6.01	35.69	38.59
Net Cash Flow	63.47	81.74	144.61	-46.6	-37.19	-176.84
Free Cash Flow	60.49	53.9	-306.2	-467.36	-495.7	-441.35
Free Cash Flow Growth	12.23%	-	-	-	-	-
FCF Margin	6.99%	7.48%	-84.20%	-175.23%	-968.65%	-5674.38%
Free Cash Flow Per Share	0.97	0.89	-5.29	-8.30	-8.84	-8.06
Levered Free Cash Flow	552.96	-183.6	-231.64	-408.2	-69.26	-432.8
Unlevered Free Cash Flow	105.98	-79.74	-258.73	-515.13	-550.03	-500.58

SEC Filings: 10-K · 10-Q